Allspring Global Investments’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Allspring Global Investments’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,474	Closed	-$104K	–	2905
2023 Q1	$104K	Buy	4,474 +1,235	+38%	+$29.4K	﹤0.01%	2039
2022 Q4	$84.9K	Sell	3,239 -71	-2%	-$1.57K	﹤0.01%	2135
2022 Q3	$65K	Buy	+3,310	New	+$66.4K	﹤0.01%	2248
2022 Q1	–	Sell	-11,924	Closed	-$194K	–	3084
2021 Q4	$194K	Buy	+11,924	New	+$170K	﹤0.01%	2642

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Allspring Global Investments's KDNY Position: Q2 2023 in Review

Allspring Global Investments sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 4,474 shares — an estimated $104K sold.

Allspring Global Investments first reported a position in KDNY in Q4 2021 and held it in 4 quarters. The position peaked at $194K in Q4 2021. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

Allspring Global Investments reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Allspring Global Investments sold 4,474 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $104K.
Allspring Global Investments first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
Allspring Global Investments's Chinook Therapeutics, Inc. Common Stock position peaked at $194K in Q4 2021.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Allspring Global Investments's 13F filing for Q2 2023, filed 18 Jul 2023.